0001354457-23-000651.txt : 20230908
0001354457-23-000651.hdr.sgml : 20230908
20230908101120
ACCESSION NUMBER: 0001354457-23-000651
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20230908
DATE AS OF CHANGE: 20230908
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
BUSINESS ADDRESS:
STREET 1: 25-28 NORTH WALL QUAY
CITY: DUBLIN
STATE: L2
ZIP: D01 H104
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 414 COMMERCE DRIVE
STREET 2: STE 120
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001641640
Nabriva Therapeutics plc
001-37558
25-28 North Wall Quay
IFSC Dublin 1
L2
IRELAND
D01 H104
353 1 649 2000
Ordinary shares
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2023-09-08
EX-99.25
2
nbrvdelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, September 8, 2023,
Nabriva Therapeutics plc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the ordinary shares of Nabriva Therapeutics plc (the Company),
effective at the opening of the trading session on September 18, 2023.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5550(b).
The Company was notified of the Staff determination on
July 21, 2023. The Company did not appeal the Staff determination
to the Hearings Panel. The Company securities were suspended on
August 1, 2023. The Staff determination to delist the Company
securities became final on August 1, 2023.